Sarepta Plunges Again After Europe Rejects Elevidys

zerohedge.com/markets/sarepta-plunges-again-after-europe-rejects-elevidys

Sarepta Plunges Again After Europe Rejects Elevidys

Perhaps analysts at HC Wainwright & Co. were right about their 12-month zero-dollar price target for Sarepta Therapeutics.
Following Sarepta's withdrawal of its Duchenne muscular dystrophy gene therapy drug from U.S. markets earlier…

This story appeared on zerohedge.com, 2025-07-25 13:20:00.
The Entire Business World on a Single Page. Free to Use →